Merck KGaA (MKKGY) Stock Price, News & Analysis

Company Overview

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. Merck KGaA operates independently from the U.S.-based Merck & Co., Inc., which uses the name MSD in markets outside the United States and Canada.

The company operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, bioprocessing equipment and services used by academic institutions, pharmaceutical manufacturers and other industrial customers. Healthcare activities include prescription medicines and specialty treatments, with products addressing areas such as oncology, neurology and immunology, as well as fertility and endocrinology.

Merck KGaA’s Electronics business develops materials and solutions used in semiconductor manufacturing and display technologies, including specialty chemicals, photoresists and materials for liquid-crystal and OLED applications. The company serves customers in markets around the world through an international research, manufacturing and commercial network. Belén Garijo serves as chair of the company’s executive board and chief executive officer.

Key Stats

• Today's Range: $30.48 to $30.72
• 50-Day Range: $30.49 to $33.83
• 52-Week Range: $23.73 to $34.19
• Volume: 56,337 shs
• Average Volume: 44,219 shs
• Market Capitalization: $19.70 billion
• P/E Ratio: 15.72
• Dividend Yield: 1.15%
• Price Target: N/A
• Consensus Rating: Hold

Merck KGaA Stock Analysis - MarketRank™

Merck KGaA scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Hold

Consensus Rating

Merck KGaA has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Merck KGaA has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 5.21%

Earnings Growth

Earnings for Merck KGaA are expected to grow by 5.21% in the coming year, from $1.92 to $2.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merck KGaA is 15.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merck KGaA is 15.72, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.82.

Price to Earnings Growth Ratio

Merck KGaA has a PEG Ratio of 2.90. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Merck KGaA has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Merck KGaA has been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Merck KGaA has recently decreased by 80.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Merck KGaA pays a meaningful dividend of 1.13%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Merck KGaA does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Merck KGaA is 18.04%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Merck KGaA will have a dividend payout ratio of 17.33% next year. This indicates that Merck KGaA will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Merck KGaA has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Merck KGaA this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merck KGaA insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.10% of the stock of Merck KGaA is held by institutions.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 9/11/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MKKGY
• Previous Symbol: OTCMKTS:MKKGY
• CIK: N/A
• Web: www.merckgroup.com
• Phone: 496151720
• Fax: 49-61-5172-2000
• Employees: 62,461
• Year Founded: 1668

Profitability

• EPS (Trailing Twelve Months): $1.94
• Trailing P/E Ratio: 15.72
• Forward P/E Ratio: 15.88
• P/E Growth: 2.9
• Net Income: $2.95 billion
• Net Margins: 11.20%
• Pretax Margin: 15.44%
• Return on Equity: 8.19%
• Return on Assets: 4.61%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 1.51
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $23.87 billion
• Price / Sales: 0.83
• Cash Flow: $8.49 per share
• Price / Cash Flow: 3.59
• Book Value: $50.18 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 646,210,000
• Free Float: N/A
• Market Cap: $19.70 billion
• Optionable: Not Optionable
• Beta: 0.96